Navu mono-aidtherapy can change GBM's tumor immune microenvironment

Glioblastoma (GBM) is a highly malignant central nervous system tumorAfter surgery and chemotherapy, the survival of patients improved only slightlyKurt ASchalper of the Department of Pathology at Yale School of Medicine in New Haven, Connecticut, USA, conducted a one-arm Phase II clinical trial (NCT02550249) to assess the value of nivolumab as a new complementary treatment for glioblastomaThe findings were published in the March 2019 issue of Nature Medicineresearch methodsstudy included a total of 30 glioblastoma patients, of which 3 were primary tumor patients and 27 patients with tumor recurrencePatients were treated with 2 mg/kg navuccino 2 weeks prior to surgery, given the same dose every 2 weeks after surgery, until tumor progression or serious drug side effects were detected in imagingPrimary tumor patients in the 66 days after surgery to discontinue Navudan resistance, the standard chemotherapy, 2 patients continued to use Navu-da anti-chemotherapy after the end of chemotherapy, no toxic side effectsPatients with recurrent tumors received Navu-mono-treatment every 2 weeks after surgery, and decided the time to discontinue the drug according to imaging showing the progression of the tumor, the toxic reaction of the drug, and the individual wishes of the patientThe medians of non-progressive life (PFS) and total survival (OS) were 4.1 months and 7.3 months, respectivelythe results of the study
Navudan is a programoid death molecule (PD-1) blocker, blocking pD-1-mediated immunosuppressive pathways and promoting anti-tumor immune effectsThe researchers compared immune-related molecular and cytological samples before and after the surgery of Navu-dan-resistant patients, and found that after Navu-dal-resistant treatment, the expression of active cytokines of mediated immune response in patients significantly improved, and increased the abundance of T-cell subgroups; at the same time, the researchers performed immunofluorescent staining at the cytological level on the surgical pathological tissue before and after the treatment of navudonaresisttomy, and detected the immersion differences of various cells in the tumor microenvironment (Figure 1)Multiple immunofluorescent detection of immune cells in tumor microenvironmentbefores before and after the treatment of Navu-mono-resistanceconclusions the final authors point out that navudan anti-treatment GBM-assisted new therapy can enhance the transscribed expression of chemctosis factors, enhance the leaching of T lymphocytes and other immune cells in tumors, increase the diversity of TCR cloning, support the local immunomodulation of tumors, and kill tumor cells The new complementary therapy has no obvious clinical benefits for PATIENTs with GBM rescue surgery, but in 3 original GBM patients, 2 survived 33 months and 28 months respectively after using Navu-monoresistance before and after the initial operation, which is worth exploring in depth The treatment of Navu-monoantigen triggers an anti-tumor immune response, while pD-1 blocking therapy alone is not enough to delay or prevent disease progression, and immunoand and non-immune combination therapy may offer new treatment potential.